Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

被引:67
作者
Figueras-Aloy J. [1 ]
Manzoni P. [2 ]
Paes B. [3 ]
Simões E.A.F. [4 ]
Bont L. [5 ]
Checchia P.A. [6 ]
Fauroux B. [7 ]
Carbonell-Estrany X. [8 ]
机构
[1] Hospital Clínic, Catedràtic de Pediatria, Universitat de Barcelona, Barcelona
[2] Sant’Anna Hospital, Turin
[3] Department of Paediatrics (Neonatal Division), McMaster University, Hamilton
[4] University of Colorado School of Medicine, Aurora, CO
[5] University Medical Center Utrecht, Utrecht
[6] Baylor College of Medicine, Texas Children’s Hospital Houston, Texas
[7] Necker University Hospital and Paris 5 University, Paris
[8] Hospital Clinic, Institut d’Investigacions Biomediques August Pi Suñer (IDIBAPS), Barcelona
关键词
Burden; Gestational age; Hospitalization; Immunoprophylaxis; Preterm; Respiratory syncytial virus; Risk;
D O I
10.1007/s40121-016-0130-1
中图分类号
学科分类号
摘要
Introduction: The REGAL (RSV Evidence—a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This second publication covers the risk and burden of RSV infection in preterm infants born at <37 weeks’ gestational age (wGA) without chronic lung disease or congenital heart disease. Methods: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015. Studies reporting data for hospital visits/admissions for RSV infection among preterm infants as well as studies reporting RSV-associated morbidity, mortality, and risk factors were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Results: 2469 studies were identified of which 85 were included. Preterm infants, particularly those born at lower wGA, tended to have higher RSV hospitalization (RSVH) rates compared with otherwise healthy term infants (high SOE). RSVH rates ranged from ~5 per 1000 children to >100 per 1000 children with the highest rates shown in the lowest gestational age infants (high SOE). Independent risk factors associated with RSVH include: proximity of birth to the RSV season, living with school-age siblings, smoking of mother during pregnancy or infant exposure to environmental smoking, reduced breast feeding, male sex, and familial atopy (asthma) (high SOE). Predictive models can identify 32/33–35 wGA infants at risk of RSVH (high SOE). Conclusion: RSV infection remains a major burden on Western healthcare systems and is associated with significant morbidity. Further studies focusing on the prevalence and burden of RSV in different gestational age cohorts, the changing risk of RSVH during the first year of life, and on RSV-related mortality in preterm infants are needed to determine the true burden of disease. Funding: AbbVie. © 2016, The Author(s).
引用
收藏
页码:417 / 452
页数:35
相关论文
共 103 条
  • [21] Report of the Committee on Infectious Diseases, 29th Edition. Editor: Larry K. Pickering, MD, FAAP
  • [22] Associate Editors: Carol J. Baker, MD, FAAP
  • [23] David W. Kimberlin, MD, FAAP
  • [24] Sarah S, (2012)
  • [25] Samson L., Prevention of respiratory syncytial virus infection, Paediatr Child Health, 14, pp. 521-532, (2009)
  • [26] Figueras-Aloy J., Carbonell-Estrany X., de Estandares de la SENeo C., Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial, An Pediatr, 82, 199, pp. e1-e2, (2015)
  • [27] Bollani L., Baraldi E., Chirico G., Dotta A., Lanari M., Del V.A., Et al., Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital, J Pediatr, 41, (2015)
  • [28] Bont L., Checchia P., Fauroux B., Figueras-Aloy J., Manzoni P., Paes B., Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries, (2016)
  • [29] Oxford Centre for Evidence-Based Medicine
  • [30] Oxford Centre for Evidence-Based Medicine